Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
Glycomine has raised $115.0M in total funding. The most recent round was Series C. The last funding was announced in April 2025.
Glycomine's investors include Novo Holdings, Abingworth, Sanofi Ventures, Mission BioCapital, Aberdeen.
Glycomine is headquartered in San Carlos, United States.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
Glycomine is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Glycomine — Funding & Investors." VCBacked, April 16, 2025, https://www.vcbacked.co/company/glycomine. Accessed October 29, 2026.
VCBacked. (2025). Glycomine — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/glycomine
{{cite web |title=Glycomine — Funding & Investors |url=https://www.vcbacked.co/company/glycomine |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated